Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients

Journal of Dermatology

Volumn 38, Issue 9, 2011, Pages 880-886

  Hofmann, Maja A ^a   Schicke, Bernd ^a   Fritsch, Andreas ^a   Biesold, Susanne ^a   Gussmann, Felix ^a   KÜchler, Ingeborg ^a   Voit, Christiane ^a   Trefzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

lymph node metastases; melanoma; melanoma inhibitory activity; sentinel lymph node biopsy; serum marker; stage III

Indexed keywords

LACTATE DEHYDROGENASE; MELANOMA INHIBITORY ACTIVITY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SERUM; SURVIVAL RATE;

EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052077119     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01219.x     Document Type: Article

References (25)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
2. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage-1 melanoma of limbs. N Engl J Med 1977; 297: 627-630. (Pubitemid 8200048)
3. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-263.
4. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
5. Morton DL, Scheri RP, Balch CM,. Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? Ann Surg Oncol 2007; 14: 2437-2439. (Pubitemid 47389586)
6. Utikal J, Schadendorf D, Ugurel S,. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 2007; 298: 469-477. (Pubitemid 46295062)
7. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100 beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003; 97: 1737-1745. (Pubitemid 36350717)
8. Bogdahn U, Apfel R, Hahn M, et al. Autocrine tumor-cell growth-inhibiting activities from human-malignant melanoma. Cancer Res 1989; 49: 5358-5363. (Pubitemid 19240474)
9. Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-3153. (Pubitemid 27351728)
10. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891-1896. (Pubitemid 29269262)
11. Faries MB, Gupta RK, Ye X, et al. Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest 2007; 25: 285-293. (Pubitemid 47185072)
12. Krahn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral flood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21: 1311-1316. (Pubitemid 32494139)
13. Vucetic B, Rogan SA, Hrabac P, et al. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res 2008; 18: 201-207. (Pubitemid 351684665)
14. Hofmann MA, Gussmann F, Fritsche A, et al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 2009; 19: 17-23.
15. Garbe C, Schadendorf D,. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 2003; 26: 241-246. (Pubitemid 36831212)
16. Rutkowski P, Nowecki ZI, Kulik J, Ruka W, Siedlecki JA,. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Res 2008; 18: 246-252.
17. John T, Black MA, Toro TT, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008; 14: 5173-5180.
18. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D,. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20: 2203-2207. (Pubitemid 30636209)
19. Auge JM, Molina R, Filella X, et al. S-100 beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 2005; 25: 1779-1782. (Pubitemid 40896802)
20. Matsushita Y, Hatta N, Wakamatsu K, Takehara K, Ito S, Takata M,. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Melanoma Res 2002; 12: 319-323. (Pubitemid 34816436)
21. Meral R, Duranyildiz D, Tas F, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res 2001; 11: 627-632. (Pubitemid 33152354)
22. Brochez L, Naeyaert JM,. Serological markers for melanoma. Br J Dermatol 2000; 143: 256-268. (Pubitemid 30650391)
23. Banfalvi T, Gilde K, Boldizsar M, Kremmer T,. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma 2002; 49: 121-125. (Pubitemid 34493674)
24. Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W,. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol 2008; 159: 597-605.
25. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL,. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004; 51: 399-405. (Pubitemid 39178667)